|
|
|
|
|
|
Sponsors and Collaborators: |
Swiss Pediatric Oncology Group Swiss Cancer League Bayer |
Information provided by: | Swiss Pediatric Oncology Group |
ClinicalTrials.gov Identifier: | NCT00107081 |
The purpose of this study is to determine whether, in children with cancer presenting with fever in severe chemotherapy-induced neutropenia at low risk for medical complications, oral antibiotics in an outpatient setting after an initial phase of intravenous antibiotics and in-hospital observation for 8 to 22 hours, is not inferior as to safety and efficacy compared to continued intravenous antibiotics given in-hospital.
Condition | Intervention | Phase |
Fever Neutropenia Cancer |
Drug: ciprofloxacin and amoxicillin Procedure: Outpatient management |
Phase III |
MedlinePlus related topics: | Antibiotics Cancer Fever |
ChemIDplus related topics: | Amoxicillin Amoxicillin sodium Amoxicillin trihydrate Ciprofloxacin Ciprofloxacin hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Prospective Multi-Center Study on Pediatric Patients With Fever in Severe Chemotherapy Induced Neutropenia, Including a Randomized Comparison of Outpatient Management and Oral Antimicrobial Therapy Versus Inpatient Management and Intravenous Antimicrobial Therapy in a Subgroup With Low Risk of Adverse Events (Low-Risk Subgroup Study) |
Enrollment: | 70 |
Study Start Date: | January 2004 |
Study Completion Date: | December 2007 |
Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
Details on antimicrobial therapy
Details on clinical and laboratory controls
Ages Eligible for Study: | 1 Year to 18 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Germany | |||||
Pediatric Hematology/Oncology, University Hospital St. Hedwig | |||||
Regensburg, Germany, D-93049 | |||||
Pediatric Hematology/Oncology, University Children's Hospital | |||||
Bonn, Germany, D-53113 | |||||
Pediatric Hematology/Oncology, University Children's Hospital | |||||
Duesseldorf, Germany, D-40225 | |||||
Pediatric Hematology/Oncology, University Children's Hospital | |||||
Freiburg, Germany, D-79106 | |||||
Pediatric Hematology/Oncology, University Children's Hospital von Hauner | |||||
Munich, Germany, D-80337 | |||||
Netherlands | |||||
Pediatric Hematology/Oncology, University Children's Hospital | |||||
Groningen, Netherlands, NL-9700 | |||||
Switzerland | |||||
Pediatric Hematology/Oncology, University Children's Hospital | |||||
Zurich, Switzerland, CH-8032 | |||||
Pediatric Hematology/Oncology, University Children's Hospital | |||||
Bern, Switzerland, CH-3010 | |||||
Pediatric Hematology/Oncology, University Children's Hospital | |||||
Geneva, Switzerland, CH-1205 | |||||
Pediatric Hematology/Oncology, University Children's Hospital | |||||
Lausanne, Switzerland, CH-1011 | |||||
Pediatric Hematology/Oncology, Children's Hospital | |||||
Lucerne, Switzerland, CH-6004 | |||||
Pediatric Hematology/Oncology, University Children's Hospital | |||||
Basel, Switzerland, CH-4005 |
Swiss Pediatric Oncology Group |
Swiss Cancer League |
Bayer |
Study Chair: | Roland A Ammann, MD | Pediatric Hematology/Oncology, University Children's Hospital, Inselspital, CH-3010 Bern, Switzerland |
Study Director: | Christoph Aebi, MD | University Children's Hospital, Bern, Switzerland |
Principal Investigator: | Maja Beck-Popovic, MD | Pediatric Hematology/Oncology, University Children's Hospital, Lausanne, Switzerland |
Principal Investigator: | Eveline SJM de Bont, MD | Pediatric Hematology/Oncology, University Children's Hospital, Groningen, The Netherlands |
Principal Investigator: | Thomas Kuehne, MD | Pediatric Hematology/Oncology, University Children's Hospital, Basel, Switzerland |
Study Director: | David Nadal, MD | University Children's Hospital, Zurich, Switzerland |
Principal Investigator: | Felix Niggli, MD | Pediatric Hematology/Oncology, University Children's Hospital, Zurich, Switzerland |
Principal Investigator: | Arne Simon, MD | Pediatric Hematology/Oncology, University Children's Hospital, Bonn, Germany |
Study Director: | Nicole Bodmer, MD | Pediatric Hematology/Oncology, University Children's Hospital, Zurich, Switzerland |
Principal Investigator: | Hulya Ozsahin, MD | Pediatric Hematology/Oncology, University Children's Hospital, Geneva, Switzerland |
Responsible Party: | Swiss Pediatric Oncology Group; Roland A Ammann, MD |
Study ID Numbers: | SPOG 2003 FN, Umbrella Network Trial 2004.3, OCS - 01466-02-2004 |
First Received: | April 4, 2005 |
Last Updated: | January 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00107081 |
Health Authority: | Switzerland: Swissmedic; Germany: Federal Institute for Drugs and Medical Devices |
|
|
|
|
|